Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 6/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
SWAV Stock Overview
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide.
ShockWave Medical Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$197.69 |
52 Week High | US$249.73 |
52 Week Low | US$113.36 |
Beta | 1.48 |
1 Month Change | 18.53% |
3 Month Change | 2.56% |
1 Year Change | 1.86% |
3 Year Change | 246.28% |
5 Year Change | n/a |
Change since IPO | 548.16% |
Recent News & Updates
Returns Are Gaining Momentum At ShockWave Medical (NASDAQ:SWAV)
What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Shareholder Returns
SWAV | US Medical Equipment | US Market | |
---|---|---|---|
7D | 25.0% | 7.0% | 6.6% |
1Y | 1.9% | -23.7% | -18.5% |
Return vs Industry: SWAV exceeded the US Medical Equipment industry which returned -25.1% over the past year.
Return vs Market: SWAV exceeded the US Market which returned -20.5% over the past year.
Price Volatility
SWAV volatility | |
---|---|
SWAV Average Weekly Movement | 12.5% |
Medical Equipment Industry Average Movement | 10.5% |
Market Average Movement | 8.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SWAV is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: SWAV's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 657 | Doug Godshall | https://www.shockwavemedical.com |
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors.
ShockWave Medical Fundamentals Summary
SWAV fundamental statistics | |
---|---|
Market Cap | US$7.08b |
Earnings (TTM) | US$28.99m |
Revenue (TTM) | US$298.88m |
244.1x
P/E Ratio23.7x
P/S RatioIs SWAV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SWAV income statement (TTM) | |
---|---|
Revenue | US$298.88m |
Cost of Revenue | US$46.44m |
Gross Profit | US$252.44m |
Other Expenses | US$223.46m |
Earnings | US$28.99m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 08, 2022
Earnings per share (EPS) | 0.81 |
Gross Margin | 84.46% |
Net Profit Margin | 9.70% |
Debt/Equity Ratio | 6.5% |
How did SWAV perform over the long term?
See historical performance and comparisonValuation
Is SWAV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SWAV?
Other financial metrics that can be useful for relative valuation.
What is SWAV's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | US$7.08b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 23.2x |
Enterprise Value/EBITDA | 193.5x |
PEG Ratio | 7.2x |
Price to Sales Ratio vs Peers
How does SWAV's PS Ratio compare to its peers?
SWAV PS Ratio vs Peers |
---|
Company | PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 9.7x |
Price-To-Sales vs Peers: SWAV is expensive based on its Price-To-Sales Ratio (23.7x) compared to the peer average (9.7x).
Price to Earnings Ratio vs Industry
How does SWAV's PE Ratio compare vs other companies in the U.S. Medical Equipment Industry?
Price-To-Sales vs Industry: SWAV is expensive based on its Price-To-Sales Ratio (23.7x) compared to the US Medical Equipment industry average (3.8x)
Price to Sales Ratio vs Fair Ratio
What is SWAV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 23.7x |
Fair PS Ratio | 16.8x |
Price-To-Sales vs Fair Ratio: SWAV is expensive based on its Price-To-Sales Ratio (23.7x) compared to the estimated Fair Price-To-Sales Ratio (16.8x).
Share Price vs Fair Value
What is the Fair Price of SWAV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SWAV ($197.69) is trading above our estimate of fair value ($39.5)
Significantly Below Fair Value: SWAV is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: SWAV is poor value based on its PEG Ratio (7.2x)
Discover undervalued companies
Future Growth
How is ShockWave Medical forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score
6/6Future Growth Score 6/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
33.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SWAV's forecast earnings growth (33.9% per year) is above the savings rate (1.9%).
Earnings vs Market: SWAV's earnings (33.9% per year) are forecast to grow faster than the US market (13.9% per year).
High Growth Earnings: SWAV's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SWAV's revenue (24.9% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: SWAV's revenue (24.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SWAV's Return on Equity is forecast to be high in 3 years time (28%)
Discover growth companies
Past Performance
How has ShockWave Medical performed over the past 5 years?
Past Performance Score
3/6Past Performance Score 3/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
11.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SWAV has high quality earnings.
Growing Profit Margin: SWAV became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: SWAV has become profitable over the past 5 years, growing earnings by 11.9% per year.
Accelerating Growth: SWAV has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SWAV has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: SWAV's Return on Equity (10.8%) is considered low.
Discover strong past performing companies
Financial Health
How is ShockWave Medical's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: SWAV's short term assets ($309.9M) exceed its short term liabilities ($51.0M).
Long Term Liabilities: SWAV's short term assets ($309.9M) exceed its long term liabilities ($53.7M).
Debt to Equity History and Analysis
Debt Level: SWAV has more cash than its total debt.
Reducing Debt: Insufficient data to determine if SWAV's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: SWAV's debt is well covered by operating cash flow (198.3%).
Interest Coverage: SWAV's interest payments on its debt are well covered by EBIT (29.6x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is ShockWave Medical current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SWAV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SWAV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SWAV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SWAV's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SWAV has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
4.3yrs
Average management tenure
CEO
Doug Godshall (56 yo)
5.08yrs
Tenure
US$7,317,042
Compensation
Mr. Douglas E. Godshall, also known as Doug, M.B.A., has been the Chief Executive Officer and President of Shockwave Medical, Inc. since May 10, 2017. Mr. Godshall serves as the Chairman at Saluda Medical...
CEO Compensation Analysis
Compensation vs Market: Doug's total compensation ($USD7.32M) is about average for companies of similar size in the US market ($USD8.47M).
Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: SWAV's management team is considered experienced (4.3 years average tenure).
Board Members
Experienced Board: SWAV's board of directors are considered experienced (4.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SWAV insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.
Top Shareholders
Company Information
ShockWave Medical, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: ShockWave Medical, Inc.
- Ticker: SWAV
- Exchange: NasdaqGS
- Founded: 2009
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$7.076b
- Shares outstanding: 35.79m
- Website: https://www.shockwavemedical.com
Number of Employees
Location
- ShockWave Medical, Inc.
- 5403 Betsy Ross Drive
- Santa Clara
- California
- 95054
- United States
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/24 00:00 |
End of Day Share Price | 2022/06/24 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.